Herrera AF, Goy A, Mehta A, et al. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma. Am J Hematol. 2020;95:18--27. 10.1002/ajh.25659 31621094

Presented in part at the 30th EORTC‐NCI‐AACR Symposium; November 13‐16, 2018; Dublin, Ireland.

**Funding information** Pharmacyclics LLC, an AbbVie Company

1. INTRODUCTION {#ajh25659-sec-0001}
===============

Diffuse large B‐cell lymphoma (DLBCL) and follicular lymphoma (FL) are the most common subtypes of non‐Hodgkin lymphoma in adults.[1](#ajh25659-bib-0001){ref-type="ref"}, [2](#ajh25659-bib-0002){ref-type="ref"}, [3](#ajh25659-bib-0003){ref-type="ref"}, [4](#ajh25659-bib-0004){ref-type="ref"} Although most patients respond to first‐line chemoimmunotherapy, a substantial proportion of patients with DLBCL and most patients with FL will eventually relapse or have refractory disease.[1](#ajh25659-bib-0001){ref-type="ref"}, [2](#ajh25659-bib-0002){ref-type="ref"}, [3](#ajh25659-bib-0003){ref-type="ref"}, [4](#ajh25659-bib-0004){ref-type="ref"}, [5](#ajh25659-bib-0005){ref-type="ref"} The treatment of relapsed/refractory DLBCL and FL remains challenging, with a minority of patients with DLBCL achieving durable remission and patients with FL experiencing decreased duration of remission with successive therapies.[1](#ajh25659-bib-0001){ref-type="ref"}, [2](#ajh25659-bib-0002){ref-type="ref"}, [3](#ajh25659-bib-0003){ref-type="ref"}, [4](#ajh25659-bib-0004){ref-type="ref"}, [5](#ajh25659-bib-0005){ref-type="ref"} Effective, well‐tolerated therapy for relapsed/refractory DLBCL and FL remains an unmet need.

Ibrutinib, a first‐in‐class, once‐daily inhibitor of Bruton\'s tyrosine kinase (BTK), is approved in the United States, Europe, and other countries for the treatment of various B‐cell malignancies.[6](#ajh25659-bib-0006){ref-type="ref"}, [7](#ajh25659-bib-0007){ref-type="ref"} In addition to BTK, ibrutinib has also been shown to inhibit interleukin 2‐inducible kinase, resulting in suppression of Th2 cells and potentiation of Th1‐mediated immunity.[8](#ajh25659-bib-0008){ref-type="ref"} Although ibrutinib has demonstrated clinically meaningful efficacy against many B‐cell malignancies, the ORR to ibrutinib alone for patients with relapsed/refractory FL is approximately 21%‐38% among current studies, and the ORR for patients with relapsed/refractory DLBCL receiving single‐agent ibrutinib is 28%, motivating the investigation of combination approaches to improve response.[9](#ajh25659-bib-0009){ref-type="ref"}, [10](#ajh25659-bib-0010){ref-type="ref"}, [11](#ajh25659-bib-0011){ref-type="ref"}

Programmed death (PD)‐1, an inhibitory receptor expressed by activated T cells, limits autoimmunity by suppressing T cell--mediated immune responses following engagement by its ligands, PD‐L1 or PD‐L2.[12](#ajh25659-bib-0012){ref-type="ref"} Tumors frequently exploit the PD‐1 pathway to evade immune surveillance via upregulation of PD‐1 and/or PD‐L1 expression on tumor cells and tumor‐associated immune cells.[13](#ajh25659-bib-0013){ref-type="ref"} Gene amplification of the PD‐1 ligands and overexpression of PD‐L1 on tumor cells and tumor‐associated macrophages is present in certain subsets of patients with DLBCL,[14](#ajh25659-bib-0014){ref-type="ref"}, [15](#ajh25659-bib-0015){ref-type="ref"} and PD‐L1 expression is associated with poorer survival after standard therapy.[16](#ajh25659-bib-0016){ref-type="ref"} High PD‐1 expression on CD4+ tumor‐infiltrating lymphocytes has been observed in FL.[17](#ajh25659-bib-0017){ref-type="ref"}, [18](#ajh25659-bib-0018){ref-type="ref"}, [19](#ajh25659-bib-0019){ref-type="ref"} Durvalumab is an anti--PD‐L1 antibody that restores antitumor immune responses.[20](#ajh25659-bib-0020){ref-type="ref"} Other PD‐1/PD‐L1--targeted agents have demonstrated antitumor activity in patients with DLBCL or FL.[21](#ajh25659-bib-0021){ref-type="ref"}, [22](#ajh25659-bib-0022){ref-type="ref"}, [23](#ajh25659-bib-0023){ref-type="ref"}, [24](#ajh25659-bib-0024){ref-type="ref"} Notably, data from murine lymphoma models suggest that ibrutinib combined with an anti--PD‐L1 antibody may have synergistic antitumor activity.[25](#ajh25659-bib-0025){ref-type="ref"} Together, the immune‐modulating properties of ibrutinib, PD‐1/PD‐L1 expression observed in patients with DLBCL and FL, and preclinical data suggesting synergy between the agents provide a strong rationale for investigating the combination of ibrutinib with PD‐1/PD‐L1 blockade in FL and DLBCL.

We therefore performed a phase 1b/2 study to evaluate the safety and antitumor activity of the combination of ibrutinib and durvalumab in patients with relapsed/refractory DLBCL or FL.

2. METHODS {#ajh25659-sec-0002}
==========

2.1. Patients {#ajh25659-sec-0003}
-------------

Key eligibility criteria included age ≥18 years; pathologically confirmed DLBCL, with subtype identified via gene expression or immunohistochemistry tests, or FL (grade 1, 2, or 3A) according to World Health Organization criteria; relapsed/refractory disease to at least one line of therapy; measurable disease (≥1 lesion \>1.5 cm in longest dimension); adequate hematological function independent of transfusion and growth factor support; adequate hepatic and renal function; prothrombin time \<1.5 times the upper limit of normal (ULN) and activated partial thromboplastin time \<1.5 times ULN; and Eastern Cooperative Oncology Group performance status of 0 or 1. In the phase 2 portion of the study within the DLBCL cohort, patients with germinal center B‐cell (GCB) and non‐GCB subtypes were to be enrolled in a 1:1 ratio.

2.2. Study design, treatment, and oversight {#ajh25659-sec-0004}
-------------------------------------------

This was an open‐label, multicenter phase 1b/2 study conducted at 12 centers in the United States from May 2015 to February 2018. The phase 1b portion of the study employed a 6 + 3 de‐escalation design to determine the recommended phase 2 dose of ibrutinib in combination with durvalumab, with starting doses of ibrutinib 560 mg and durvalumab 10 mg/kg in cohort 1. The first patient in each dose cohort served as a sentinel patient who was observed for a period of ≥3 days to monitor for any unexpected acute or overlapping toxicities before dosing of the next patient. If two of the first six patients experienced a dose‐limiting toxicity (DLT) during cycle 1, an additional three patients were to be enrolled. If ≤1 of six or ≤2 of nine patients experienced a DLT, the dose level was to be defined as the recommended phase 2 dose. If ≥2 of six or ≥3 of nine DLTs were observed, dose de‐escalation cohorts (ibrutinib to 420 mg and/or durvalumab to 3 mg/kg) were available to be opened. In the phase 2 portion of the study, patients were treated at the recommended phase 2 dose as determined in phase 1b. In all cohorts, ibrutinib was administered orally once daily for up to 3 years in combination with durvalumab given intravenously on days 1 and 15 of each 28‐day cycle for up to 12 cycles in the absence of progressive disease (PD) or unacceptable toxicity.

This study was conducted according to principles of the Declaration of Helsinki and the International Conference on Harmonisation Guidelines for Good Clinical Practice, The study was approved by the institutional review boards, research ethics boards, or independent ethics committees of participating institutions. All patients provided written informed consent. This study was registered with <http://clinicaltrials.gov>, number NCT02401048.

2.3. Outcomes and assessments {#ajh25659-sec-0005}
-----------------------------

The primary endpoints of the phase 1b portion of the study were to determine the recommended phase 2 dose of ibrutinib in combination with durvalumab as well as safety and tolerability; secondary endpoints included overall response rate (ORR) and duration of response. The primary endpoint of the phase 2 portion of the study was the ORR; secondary endpoints included duration of response, progression‐free survival (PFS), overall survival (OS), safety, and tolerability.

Response evaluations were performed every three cycles until cycle 12 and every six cycles thereafter. Response was assessed by the investigator according to revised criteria for malignant lymphoma described by the International Working Group for non‐Hodgkin Lymphoma.[26](#ajh25659-bib-0026){ref-type="ref"} Adverse events (AEs) were coded using the Medical Dictionary for Regulatory Activities (version 20.0) and graded according to the National Cancer Institute Common Terminology Criteria for AEs (CTCAE), version 4.03. Treatment‐emergent adverse events (TEAEs) were defined as (1) any AE occurring after the start of study treatment and within 30 days of the last dose of ibrutinib or within 90 days after the last dose of durvalumab, (2) any study drug--related AE regardless of start date, or (3) any AE present at baseline that worsens in severity of frequency after the start of study treatment or is considered by the investigator to be study drug‐related. Treatment‐related DLTs followed guidelines provided in the CTCAE (version 4.03) and were defined as (1) any grade 3 or higher nonhematologic AE or (2) clinically relevant hematologic AE.

2.4. Biomarker analysis {#ajh25659-sec-0006}
-----------------------

Samples including peripheral blood, tumor tissue, buccal swabs, and other specimens, such as skin biopsies and fluid collected during the study, were used for biomarker analysis. Tumor tissue PD‐L1 expression was visualized via immunohistochemistry with Dako PD‐L1 22C3 pharmDx kit (Cancer Genetics, Rutherford, NJ, USA) following the kit instructions, with high PD‐L1 expression defined as ≥50% positive tumor cells.[27](#ajh25659-bib-0027){ref-type="ref"}, [28](#ajh25659-bib-0028){ref-type="ref"} DNA was extracted for genomic testing using a targeted next‐generation sequencing panel, ACE Extended Cancer Panel for DNA (Personalis, Menlo Park, CA, USA), which includes more than 1400 genes involved in cancer biology and more than 200 cancer‐related microRNAs to assess baseline tumor mutation load and characterize somatic variants. Depending on tumor tissue availability, between 1 and 2 μg of tumor DNA was used as input material for panel testing, which resulted in an average \>500‐fold coverage over the extended DNA panel footprint.

Tumor mutation burden was limited to mutations that resulted in changes in amino acids and was evaluated for correlations in patients with complete response (CR), in nonevaluable (nonresponsive) patients, or in patients with PD using a Wilcoxon rank‐sum test. The pharmacodynamics of durvalumab were assessed through measurement of the reduction in levels of free soluble PD‐L1 in serum using an enzyme‐linked immunosorbent assay.

2.5. Statistical analysis {#ajh25659-sec-0007}
-------------------------

Efficacy and safety were evaluated in all patients who received ≥1 dose of any study treatment. ORR was evaluated as the proportion of patients achieving a best overall response of CR or partial response with two‐sided 95% confidence intervals (CIs) based on exact binomial distribution (Clopper‐Pearson interval). Time to event endpoints were estimated using the Kaplan‐Meier method. Safety and tolerability were analyzed using descriptive summaries.

The statistical design for both the FL and DLBCL cohorts in phase 2, including number of patients and responders, follows the statistical framework of Simon\'s two‐stage design.[29](#ajh25659-bib-0029){ref-type="ref"} To ensure adequate statistical power to determine a difference in ORR compared with single‐agent ibrutinib for the phase 2 portion of the study, a maximum of 39 FL patients and 34 DLBCL patients (at a 1:1 ratio for GCB and non‐GCB subtypes) were enrolled. Interim analysis was planned for the first 19 response‐evaluable patients in the FL cohort and for the first nine response‐evaluable patients in the DLBCL cohort. The response‐evaluable population was defined as all patients who received ≥1 dose of any study treatment and provided ≥1 postbaseline response assessment. Cohort discontinuation was to be considered if there were ≤6 of 19 responders in the FL cohort or ≤1 of nine responders in the DLBCL cohort. However, assessment of biomarkers or tumor measurements could support continued enrollment. Enrollment continued while the first 19 FL and nine DLBCL patients underwent efficacy assessment. Enrollment was discontinued following interim analysis showing that stopping rules had been met. The primary analysis was considered the final analysis and was conducted after all patients had the opportunity to receive 12 cycles of durvalumab. The study was completed on February 5, 2018.

3. RESULTS {#ajh25659-sec-0008}
==========

Beginning on May 11, 2015, 62 patients were enrolled, including 27 with FL and 35 with DLBCL (GCB, n = 17; non‐GCB, n = 16; unknown, n = 2). The median age in all patients was 60 years (range: 22‐82), with a median of 57 years (range: 31‐79) in FL patients, 68 years (range: 22‐82) in GCB DLBCL patients, and 67 years (range: 39‐82) in non‐GCB DLBCL patients; most patients were male (62%) and white (90%) (Table [1](#ajh25659-tbl-0001){ref-type="table"}). The median time from initial diagnosis to the first dose of study treatment was 26.1 months (range: 6.0‐362.5). Most patients (85%) had received ≥2 prior treatment regimens (median: 2 regimens \[range: 1‐7\]) and 52% had disease that was refractory to the last prior regimen (Table [1](#ajh25659-tbl-0001){ref-type="table"}).

###### 

Baseline demographic and disease characteristics

  Characteristic                                                     FL                 GCB DLBCL          Non‐GCB DLBCL     All DLBCL          All patients
  ------------------------------------------------------------------ ------------------ ------------------ ----------------- ------------------ ------------------
  Median age (range), years                                          57 (31‐79)         68 (22‐82)         67 (39‐82)        67 (22‐82)         60 (22‐82)
  Sex, n (%)                                                                                                                                    
  Male                                                               17 (63)            12 (75)            8 (50)            21 (62)            38 (62)
  Female                                                             10 (37)            4 (25)             8 (50)            13 (38)            23 (38)
  Race, n (%)                                                                                                                                   
  White                                                              23 (85)            15 (94)            15 (94)           32 (94)            55 (90)
  Black/African American                                             1 (4)              0                  1 (6)             1 (3)              2 (3)
  Unknown                                                            3 (11)             1 (6)              0                 1 (3)              4 (7)
  ECOG performance status, n (%)                                                                                                                
  0                                                                  15 (56)            7 (44)             9 (56)            16 (47)            31 (51)
  1                                                                  12 (44)            9 (56)             7 (44)            18 (53)            30 (49)
  ≥2                                                                 0                  0                  0                 0                  0
  De novo DLBCL, n (%)                                               NA                 16 (100)           16 (100)          34 (100)           NA
  Bulky disease ≥5 cm, n (%)                                                                                                                    
  Yes                                                                10 (37)            7 (44)             7 (44)            14 (41)            24 (39)
  No                                                                 14 (52)            6 (38)             7 (44)            14 (41)            28 (46)
  Unknown                                                            3 (11)             3 (19)             2 (13)            6 (18)             9 (15)
  B symptoms, n (%)                                                                                                                             
  Yes                                                                9 (33)             3 (19)             4 (25)            7 (21)             16 (26)
  No                                                                 18 (67)            12 (75)            12 (75)           26 (76)            44 (72)
  Unknown                                                            0                  1 (6)              0                 1 (3)              1 (2)
  WHO grade of FL, n (%)                                                                                                                        
  1                                                                  2 (7)              NA                 NA                NA                 NA
  2                                                                  15 (56)            NA                 NA                NA                 NA
  3A                                                                 10 (37)            NA                 NA                NA                 NA
  3B                                                                 0                  NA                 NA                NA                 NA
  Number of prior regimens, n (%)                                                                                                               
  1                                                                  6 (22)             2 (13)             1 (6)             3 (9)              9 (15)
  ≥2                                                                 21 (78)            14 (88)            15 (94)           31 (91)            52 (85)
  Median number of prior regimens (range)                            2.0 (1.0‐4.0)      2.0 (1.0‐4.0)      3.0 (1.0‐7.0)     2.5 (1.0‐7.0)      2.0 (1.0‐7.0)
  Disease status following completion of last prior regimen, n (%)                                                                              
  Relapsed from CR                                                   14 (52)            2 (13)             7 (44)            9 (26)             23 (38)
  Relapsed from PR                                                   2 (7)              1 (6)              2 (13)            4 (12)             6 (10)
  Refractory (SD or PD)                                              11 (41)            13 (81)            7 (44)            21 (62)            32 (52)
  Median time from initial diagnosis to first dose (range), months   49.9 (9.8‐362.5)   14.1 (6.0‐104.1)   19.5 (7.3‐86.7)   14.7 (6.0‐104.1)   26.1 (6.0‐362.5)

Abbreviations: CR, complete response; DLBCL, diffuse large B‐cell lymphoma; ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; GCB, germinal center B‐cell; NA, not applicable; PD, progressive disease; PR, partial response; SD, stable disease; WHO, World Health Organization.

Includes patients with GCB DLBCL, non‐GCB DLBCL, and unspecified DLBCL.

Patients who received ≥1 dose of study treatment.

Sixty‐one patients received ≥1 dose of ibrutinib and 58 patients received ≥1 dose of durvalumab; one enrolled patient did not receive any study treatment. The most common reason for discontinuation of study treatment was PD (Table [S1](#ajh25659-supitem-0001){ref-type="supplementary-material"}). The median follow‐up duration was 17.3 months (range: 0.2‐28.1) for all patients, 17.0 months (range: 1.8+−28.1) for patients with FL, and 17.5 months (range: 0.2‐23.6) for patients with DLBCL.

No DLTs were observed in the phase 1b portion of the study. Therefore, the starting dose level of ibrutinib 560 mg once daily in combination with durvalumab 10 mg/kg every 2 weeks was defined as the recommended phase 2 dose level. These doses are the highest approved single‐agent dose for each study treatment.

3.1. Best overall response {#ajh25659-sec-0009}
--------------------------

Among 61 patients who were treated, 15 patients had an objective response (25%; 95% CI, 15‐37). ORRs were 26% (7/27 patients; 95% CI, 11‐46) in FL patients, 13% (2/16 patients; 95% CI, 2‐38) in patients with GCB DLBCL, and 38% (6/16 patients; 95% CI, 15‐65) in patients with non‐GCB DLBCL (Figure [1](#ajh25659-fig-0001){ref-type="fig"}A). CR was observed in one (4%) FL patient, one (6%) GCB DLBCL patient, and five (31%) non‐GCB DLBCL patients. Partial response was observed in six (22%) FL patients, one (6%) GCB DLBCL patient, and one (6%) non‐GCB DLBCL patient.

![Best response among patients with FL and DLBCL\* (A) and duration of response among patients with complete or partial response (B). CR, complete response; DLBCL, diffuse large B‐cell lymphoma; FL, follicular lymphoma; GCB, germinal center B‐cell; ORR, overall response rate; PR, partial response; SD, stable disease. \*Excludes two patients with unspecified DLBCL subtype](AJH-95-18-g001){#ajh25659-fig-0001}

Among all patients with a best response of CR or partial response, median duration of response was 11.3 months (95% CI, 5.5‐not evaluable \[NE\]). Median duration of response was NE (95% CI, 5.5‐NE) in patients with GCB DLBCL, NE (95% CI, 2.5‐NE) in those with non‐GCB DLBCL, and 11.3 months (95% CI, 8.3‐NE) in patients with FL (Figure [1](#ajh25659-fig-0001){ref-type="fig"}B).

Among patients with FL on combination treatment who had tumor measurements at baseline and at least one time point posttreatment, 19 of 26 (73%) patients exhibited a decrease in tumor size; 7 of 26 (27%) patients experienced reductions \>50% (Figure [S1](#ajh25659-supitem-0001){ref-type="supplementary-material"}). Of 18 treated patients with DLBCL who had tumor measurements at baseline and at least one posttreatment time point, 10 (56%) exhibited tumor size reduction; 8 of 18 (44%) patients had reductions \>50% (Figure [S1](#ajh25659-supitem-0001){ref-type="supplementary-material"}).

3.2. PFS and OS {#ajh25659-sec-0010}
---------------

Sixty‐one patients were included in this analysis. Overall, the median PFS was 4.6 months (95% CI, 2.6‐7.8) and the median OS was 18.1 months (95% CI, 7.8‐NE). PFS and OS were longer in patients with FL compared to those with DLBCL, with a median PFS of 10.2 months (95% CI, 4.7‐13.1); median OS was NE (95% CI, 23.6‐NE). GCB DLBCL patients had a median PFS of 2.9 months (95% CI, 1.2‐5.1) and a median OS of 5.5 months (95% CI, 3.2‐13.2), and non‐GCB DLBCL patients had a median PFS of 4.1 months (95% CI, 1.2‐10.1) and a median OS of 7.3 months (95% CI, 1.8‐NE) (Figure [2](#ajh25659-fig-0002){ref-type="fig"}). Twelve‐month PFS was 39.2% (95% CI, 18.8‐59.1) in FL patients, 12.5% (95% CI, 2.1‐32.8) in GCB DLBCL patients, and 26.7% (95% CI, 8.3‐49.6) in non‐GCB DLBCL patients.

![Progression‐free survival in patients with (A) FL and (B) DLBCL. Overall survival in in patients with (C) FL and (D) DLBCL. DLBCL, diffuse large B‐cell lymphoma; FL, follicular lymphoma; GCB, germinal center B‐cell; PFS, progression‐free survival; OS, overall survival. \*Includes patients with GCB DLBCL, non‐GCB DLBCL, and unspecified DLBCL. "+" denotes censored observation \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](AJH-95-18-g002){#ajh25659-fig-0002}

3.3. Biomarkers {#ajh25659-sec-0011}
---------------

Overall baseline tumor mutation load based on a targeted panel consisting of approximately 1400 cancer‐related genes was available for 13 patients with FL (median, 94 mutations \[range, 65‐103\]) and seven patients with DLBCL (median, 96 mutations \[range, 69‐153\]). In these patients, tumor mutational burden at baseline was not associated with best response status or maximum tumor shrinkage in either FL or DLBCL cohorts. In a small subset of patients with FL in whom tumor tissue was available (n = 11), baseline somatic variants in the *HIST1H1E* and *CANT1* genes were correlated with increased tumor shrinkage (n = 11) (Figure [S2](#ajh25659-supitem-0001){ref-type="supplementary-material"}). Additionally, the P21R single nucleotide polymorphism (SNP) in the *TNFRSF13C* gene was correlated with clinical progression in non‐GCB DLBCL patients (n = 7).

For all 41 patients with evaluable data, serum PD‐L1 was suppressed to below the limit of quantitation starting within 10 minutes of the first dose of durvalumab and continuing throughout the dosing interval, regardless of response. At baseline, only one patient with evaluable response had high (\>50%) PD‐L1 expression in tumor cells; this patient had GCB DLBCL and a best response of PD. One non‐GCB DLBCL patient with a nonevaluable response also had high PD‐L1 expression. No FL patients who were evaluable for response had \>10% PD‐L1--positive tumor cells. Due to the small number of patients with high PD‐L1 at baseline, the association of PD‐L1 expression with clinical response could not be determined.

3.4. Safety {#ajh25659-sec-0012}
-----------

Among the 61 patients who received ≥1 dose of study medication, the median duration of exposure to ibrutinib was 3.8 months (range: 0.1‐23.2) and median duration of exposure to durvalumab was 3.0 months (range: 0.0‐10.6). The most common TEAEs were generally grade 1/2 (Table [2](#ajh25659-tbl-0002){ref-type="table"}). Atrial fibrillation, arthralgia, and anemia of any grade each occurred in 10% of all patients. Grade 3/4 TEAEs were reported in 34 (56%) patients; the most frequent (≥5%) grade 3/4 TEAEs were neutropenia (n = 13, 21%), dyspnea (n = 6, 10%), fatigue (n = 5, 8%), atrial fibrillation (n = 4, 7%), peripheral edema (n = 4, 7%), and rash maculopapular (n = 4, 7%) (Table [2](#ajh25659-tbl-0002){ref-type="table"}). One FL patient had grade 5 multiple organ dysfunction syndrome. Serious TEAEs were reported in 33 (54%) patients; the most common (≥2%) serious TEAEs were atrial fibrillation (n = 4, 7%), and neutropenia, peripheral edema, pyrexia, cellulitis, pneumonia, urinary tract infection, hypercalcemia, muscular weakness, syncope, and dyspnea were reported in two patients (3%) each. Ibrutinib was discontinued because of TEAEs not related to PD in four patients (7%), including left ventricular failure, pneumonitis, peripheral edema, and autoimmune hepatitis, which occurred in one patient (2%) each. Durvalumab was discontinued because of TEAEs not related to PD in five patients (8%). The only TEAE leading to durvalumab discontinuation in ≥2 patients was pneumonitis (n = 2, 3%), with left ventricular failure, autoimmune hepatitis, and alanine aminotransferase increase occurring in one patient (2%) each.

###### 

Treatment‐emergent AEs of all grades occurring in ≥15% of all patients

  AE, n (%)                           FL        All DLBCL   All                          
  ----------------------------------- --------- ----------- --------- -------- --------- ---------
  Diarrhea                            16 (59)   1 (4)       16 (47)   1 (3)    32 (52)   2 (3)
  Fatigue                             12 (44)   1 (4)       16 (47)   4 (12)   28 (46)   5 (8)
  Nausea                              9 (33)    0           12 (35)   1 (3)    21 (34)   1 (2)
  Peripheral edema                    7 (26)    1 (4)       13 (38)   3 (9)    20 (33)   4 (7)
  Decreased appetite                  8 (30)    0           11 (32)   1 (3)    19 (31)   1 (2)
  Neutropenia                         6 (22)    4 (15)      11 (32)   9 (26)   17 (28)   13 (21)
  Vomiting                            5 (19)    0           12 (35)   0        17 (28)   0
  Upper respiratory tract infection   12 (44)   0           3 (9)     0        15 (25)   0
  Cough                               8 (30)    0           6 (18)    0        14 (23)   0
  Dyspnea                             6 (22)    2 (7)       8 (24)    4 (12)   14 (23)   6 (10)
  Rash maculopapular                  6 (22)    3 (11)      7 (21)    1 (3)    13 (21)   4 (7)
  Back pain                           6 (22)    1 (4)       5 (15)    0        11 (18)   1 (2)
  Pyrexia                             3 (11)    0           8 (24)    2 (6)    11 (18)   2 (3)
  Constipation                        3 (11)    0           7 (21)    0        10 (16)   0
  Dry mouth                           4 (15)    0           6 (18)    0        10 (16)   0
  Hyperuricemia                       5 (19)    1 (4)       5 (15)    1 (3)    10 (16)   2 (3)
  Insomnia                            4 (15)    0           6 (18)    0        10 (16)   0
  Thrombocytopenia                    4 (15)    0           6 (18)    2 (6)    10 (16)   2 (3)
  Dizziness                           3 (11)    1 (4)       6 (18)    0        9 (15)    1 (2)
  Increased tendency to bruise        5 (19)    0           4 (12)    0        9 (15)    0
  Muscle spasms                       6 (22)    0           3 (9)     0        9 (15)    0

Abbreviations: AE, adverse event; DLBCL, diffuse large B‐cell lymphoma; FL, follicular lymphoma.

Includes patients with GCB DLBCL, non‐GCB DLBCL, and unspecified DLBCL.

Overall, investigator‐defined immune‐related AEs were reported in 12 (20%) patients and were grade 3/4 in seven (11%) patients. Immune‐related AEs occurred in five of 27 (19%) patients with FL and in seven of 34 (21%) patients with DLBCL. Immune‐related AEs of any grade occurring in ≥2 patients were rash maculopapular (n = 4, 7%), pneumonitis (n = 3, 5%), and dyspnea (n = 2, 3%).

4. DISCUSSION {#ajh25659-sec-0013}
=============

Ibrutinib has been shown to suppress regulatory T cells, increase activation of cytotoxic T cells, and enhance proinflammatory cytokine secretion,[9](#ajh25659-bib-0009){ref-type="ref"}, [30](#ajh25659-bib-0030){ref-type="ref"} all of which might be expected to provide a more favorable tumor microenvironment for response to PD‐1/PD‐L1--targeted therapies. Despite this strong rationale for the combination of ibrutinib with PD‐1/PD‐L1--targeted therapy and preclinical evidence in murine lymphoma models for synergistic antitumor activity with ibrutinib plus durvalumab,[25](#ajh25659-bib-0025){ref-type="ref"} our phase 1b/2 study of ibrutinib 560 mg once daily with durvalumab 10 mg/kg every 2 weeks met the early efficacy stopping rule. This suggests that the antitumor activity of the combination was similar to what would be expected with single‐agent ibrutinib therapy in patients with relapsed/refractory FL and DLBCL.

In patients with relapsed/refractory FL, the ORR of 26% with the combination of ibrutinib plus durvalumab was similar to the ORR of 21% observed with single‐agent ibrutinib in patients with relapsed/refractory FL in the phase 2 DAWN study[9](#ajh25659-bib-0009){ref-type="ref"} and was slightly lower than the ORR of 38% observed with single‐agent ibrutinib in a phase 2 consortium in patients with relapsed/refractory FL.[10](#ajh25659-bib-0010){ref-type="ref"} Although the ORR of 26% with ibrutinib plus durvalumab was lower than the previously observed response rate in a phase 1 study of single‐agent nivolumab in patients with relapsed/refractory FL (40%),[23](#ajh25659-bib-0023){ref-type="ref"} a subsequent larger phase 2 study of nivolumab in patients with relapsed/refractory FL demonstrated that the ORR was only 4% (<http://clinicaltrials.gov>, NCT02038946). The median PFS of 10.2 months achieved by patients with FL on combination treatment in this study, in which almost 80% of patients were on at least their third line of treatment, was comparable to the median PFS of 1 year reported for patients with FL on their third‐line treatment.[31](#ajh25659-bib-0031){ref-type="ref"}

In patients with relapsed/refractory DLBCL, the ORR with the combination of ibrutinib plus durvalumab was 38% for patients with the non‐GCB subtype and 13% for those with the GCB subtype. These ORRs are consistent with those previously observed with single‐agent ibrutinib in a phase 1/2 study in patients with relapsed/refractory DLBCL, which demonstrated ORRs of 37% in patients with the activated B‐cell subtype and 5% in those with the GCB subtype.[32](#ajh25659-bib-0032){ref-type="ref"} The differential response rates between these subtypes is probably explained by chronic active B‐cell receptor signaling, which activates the NF‐ĸB pathway through BTK in non‐GCB tumors but not in GCB tumors.[33](#ajh25659-bib-0033){ref-type="ref"} DLBCL of the non‐GCB subtype might also be expected to benefit to a greater extent from PD‐1/PD‐L1--targeted therapy, as high PD‐L1 expression is only observed in non‐GCB subtypes.[14](#ajh25659-bib-0014){ref-type="ref"}, [15](#ajh25659-bib-0015){ref-type="ref"} While single‐agent PD‐1 blockade has demonstrated antitumor activity in patients with relapsed/refractory DLBCL, cell‐of‐origin analyses have not been conducted.[21](#ajh25659-bib-0021){ref-type="ref"}, [23](#ajh25659-bib-0023){ref-type="ref"} In addition, despite the promising activity observed in initial studies, a larger phase 2 study of nivolumab in relapsed/refractory DLBCL demonstrated a response rate of only 10% (n = 121).[24](#ajh25659-bib-0024){ref-type="ref"}

Tumor mutation load was not found to correlate with best response status or tumor shrinkage in either cohort based on a targeted panel of approximately 1400 cancer‐related genes. Further analysis with whole‐genome sequencing or whole‐exome sequencing would be informative for assessing global mutation load as it relates to response and tumor shrinkage. Baseline somatic variants in two genes, *CANT1* and *HIST1H1E*, were correlated with tumor shrinkage in the FL cohort, and presence of the P21R SNP in the *TNFRSF13C* gene was correlated with PD status in the non‐GCB DLBCL cohort. These correlations are based on small sample sizes and should not be considered true predictive biomarkers of response to the study regimen. These data evaluating somatic mutations associated with response are hypothesis generating, precluding definitive conclusion and requiring further confirmation. While the association of PD‐L1 expression with response could not be determined in this study, recent work has demonstrated an association between expression of PD‐L1 and CR in DLBCL patients treated with combination ibrutinib and nivolumab, an antibody to the PD‐1 receptor.[34](#ajh25659-bib-0034){ref-type="ref"} The difference in results of the two studies could be attributed to potential differences in the mechanism of action of durvalumab and nivolumab (ie, PD‐L1 rather than PD‐1 blockade), differences in methodologies for PD‐L1 detection and definitions of elevated PD‐L1 expression, or other differences in study design. Further study of correlation between response and PD‐L1 expression in FL patients may be worthwhile; however, the low antitumor activity observed with PD‐L1 blockade in FL might make such studies difficult.

Overall, safety findings with the combination of ibrutinib plus durvalumab were consistent with the known safety profiles of the individual drugs, with no new safety signals identified. The combination demonstrated acceptable tolerability at the highest dose level tested (ibrutinib 560 mg once daily in combination with durvalumab 10 mg/kg every 2 weeks), with no DLTs observed. No clinically meaningful differences were observed in the safety profile of the combination between the FL and DLBCL groups other than those expected due to disease type and duration of observation in the study.

Based on initial studies that suggested promising antitumor activity with PD‐1/PD‐L1 blockade, we and others undertook studies to evaluate the safety and activity of anti--PD‐1/PD‐L1--based combinations. However, subsequent studies of anti--PD‐1 monotherapy have demonstrated that the single‐agent response rate in FL and DLBCL is 10% or lower (<http://clinicaltrials.gov>, NCT02038946). Unfortunately, despite a strong rationale and promising preclinical data, the combination of ibrutinib and durvalumab demonstrated similar activity to single‐agent ibrutinib and was associated with the added toxicity of PD‐L1 blockade, although the safety profile of the combination was generally consistent with those known for each individual agent. Thus, this combination does not warrant further study in FL or DLBCL. As PD‐1/PD‐L1 combinations continue to be evaluated in patients with non‐Hodgkin lymphoma, it will be critical to understand the biological basis for response to those agents in order to identify target populations for further study.
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**Table S1**. Patient disposition.

**Figure S1.** Change in maximum tumor size from baseline in patients with (A) FL and (B) DLBCL. DLBCL, diffuse large B‐cell lymphoma; FL, follicular lymphoma; GCB, germinal center B‐cell. "\*" indicates best overall response of CR or PR.

**Figure S2.** Correlation of *CANT1* (A) and *HIST1H1E* (B) baseline somatic variants with maximal tumor shrinkage from baseline in FL. SPD, sum of the product of the diameters
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